The Inflation Reduction Act of 2022 (“IRA”) also eliminates the coverage gap under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program.
All entries for: Oncology
March 23, 2026
BioLineRx Ltd
Neutral Outlook
Modi'in, Israel
51-200 employees
However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
Disease Area: Oncology, Rare Disease
Drug Type: Small Molecule
March 23, 2026
Pyxis Oncology
Neutral Outlook
Boston, MA
1-50 employees
The IRA also imposes additional rebates for certain Part B and Part D drugs where relevant pricing metrics associated with the products increase faster than inflation. However, it is unclear how the IRA will be effectuated or changed under the new Trump Administration and the degree of impact that the IRA will ultimately have upon our business similarly remains unclear.
Disease Area: Oncology
Drug Type: Biologic
March 23, 2026
Sutro Biopharma
Negative Outlook
South San Francisco, CA
201-500 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
Disease Area: Oncology
Drug Type: Biologic
March 20, 2026
Cellectis S.A.
Negative Outlook
Paris, France
201-500 employees
For example, in August 2022, the United States enacted the Inflation Reduction Act of 2022 (IRA), which includes two policies that are designed to have a direct impact on drug prices. The IRA requires the federal government to negotiate prices for certain high-cost drugs covered under Medicare and requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by Medicare beneficiaries. The private sector has also sought to control healthcare costs by limiting coverage or reimbursement or requiring discounts and rebates on products. We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare industry or third party coverage and reimbursement may be enacted in the future or what effect such legislation, regulations or policies would have on our business. Any cost containment measures could significantly decrease the available coverage and the price we might establish for our potential products, which would have an adverse effect on our net revenues and operating results.
Disease Area: Hematology, Oncology
Drug Type: Biologic
March 19, 2026
Sol-Gel Technologies Ltd
Neutral Outlook
Whippany, NJ
1-50 employees
In August 2022, the Inflation Reduction Act, or IRA, was signed into law. The IRA includes multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. For example, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation.
Disease Area: Dermatology, Oncology, Rare Disease
Drug Type: Small Molecule
March 19, 2026
SELLAS Life Sciences Group
Neutral Outlook
New York, NY
1-50 employees
However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
Disease Area: Hematology, Oncology
Drug Type: Small Molecule
March 19, 2026
Acrivon Therapeutics
Negative Outlook
Watertown, MA
51-200 employees
The imposition of a “maximum fair price” under the IRA could limit the amounts that federal and state governments will pay for our products and prevent us from being able to generate revenue sufficient to cover our costs or attain profitability.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule